BVXP.L Stock Analysis
BV
Attractive
Based on Eyestock quantitative analysis, BVXP.L`s fundamental data and valuation indicate an investment grade of Attractive at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 16 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm supplies its antibody products and services to multinational clinical diagnostics companies. The company has developed a sheep hybridoma technology to produce productive cell lines that secrete sheep monoclonal antibodies (SMAs) of high affinity. The firm sells its products through direct sales and through distributors.